http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-113600148-B
Outgoing Links
| Predicate | Object |
|---|---|
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/B01J20-267 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/B01J20-28011 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61M1-3679 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/B01J20-28021 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/B01J20-28 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61M1-36 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/B01J20-26 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/B01J20-30 |
| filingDate | 2021-08-10-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2022-08-12-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2022-08-12-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | CN-113600148-B |
| titleOfInvention | Heparin-modified chitosan/cellulose microsphere-based hemoperfusion adsorbent, preparation method and application thereof |
| abstract | The invention discloses a blood perfusion adsorbent based on heparin-modified chitosan/cellulose microspheres, belonging to the technical field of biological materials. The blood perfusion adsorbent comprises cross-linked chitosan/cellulose microspheres. The cross-linked chitosan/cellulose microspheres are grafted with heparin coating, and the preparation method and application thereof are also disclosed; the adsorbent of the invention has better mechanical strength and stability, so as to better meet the requirements of blood perfusion Due to the mechanical strength of the hemoperfusion adsorbent, the abundant amino groups in the chitosan molecule make the adsorbent rich in positive charges, which can efficiently remove negatively charged endotoxins; the heparin coating in the outer layer of the adsorbent Then it can form a complex with histones, so as to quickly remove histones in the blood; the hemoperfusion adsorbent of the present invention can remove various pathogenic factors in the blood of patients with sepsis through multiple adsorption targets, thereby enhancing blood purification treatment. Therapeutic effects in patients with sepsis. |
| priorityDate | 2021-08-10-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 44.